Argan, Inc. Reports Third Quarter Fiscal 2026 Results December 4, 2025 Reports Record Backlog of $3.0 Billion
Morningstar Announces Clearer, Simplified Medalist Rating to Empower Investor Success December 4, 2025 Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today announced significant updates to its Morningstar Medalist Rating™, its comprehensive forward-looking rating for managed investments. The updated methodology, which will go live globally in April 2026, is designed to simplify the rating structure, make the rating more transparent for investors, and enhance stability—empowering [...]
IGI President & CEO Waleed Jabsheh to Present at the 17th Annual Southwest IDEAS Investor Conference on November 19, 2025 in Dallas, Texas November 17, 2025 International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that President & CEO Waleed Jabsheh will present at the Southwest IDEAS Investor Conference on Wednesday, November 19, 2025 at The Westin Las Colinas in Dallas, Texas. IGI’s presentation is scheduled to begin at 9.15 am Central Time (10.15 am Eastern time). [...]
Morningstar’s 2026 Outlook Report Delivers Global and Regional Insights for Durable Portfolios November 17, 2025 Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today published its 2026 Outlook, offering an overview of key challenges and opportunities for the year ahead. In a market defined by uncertainty, this year’s report emphasizes the value of preparation over prediction, equipping investors with strategies to focus on fundamentals and help build [...]
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros November 14, 2025 3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Double-digit growth in operating profit and shareholders’ core net income Total business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income [...]
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference November 12, 2025 Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 8:00 a.m. ET (1:00 p.m. GMT). The live webcast can be accessed in the Investors [...]
Investor Day: “TITAN Forward 2029” Growth plan November 11, 2025 Regulatory News: Titan SA (Euronext Brussels, ATHEX and Euronext Paris, TITC) announces that it is hosting today an Investor Day in Athens, Greece, where executives and members of the management team will present “TITAN Forward 2029,” TITAN’s new strategic growth plan. The plan positions TITAN for its next phase of growth, while delivering sustained long-term [...]
ReNew Announces Results for the Second Quarter for Fiscal Year 2026 (Q2 FY26), Ended September 30, 2025; Reports 84% Net Profit Increase YOY in H1 FY2026 November 10, 2025 ReNew Energy Global Plc (“ReNew” or “the Company”) (Nasdaq: RNW, RNWWW), a leading decarbonization solutions company, today announced its unaudited consolidated IFRS results for the three-month period ended September 30, 2025. Operating Highlights: As of September 30, 2025, the Company’s portfolio consisted of ~18.5 GWs (+1.1 GWh BESS), compared to ~15.6 GWs as of September [...]
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights November 6, 2025 Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million Roche to initiate the Phase 3 PARAISO clinical trial evaluating prasinezumab, a potential first-in-class anti-alpha-synuclein antibody, for early-stage Parkinson's disease by end of 2025 Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial evaluating coramitug, a potential first-in-class amyloid depleter, for ATTR amyloidosis with cardiomyopathy Novo Nordisk to present Phase 2 results for coramitug during a late-breaking session at the American Heart Association Scientific Sessions on November 10, 2025 Bristol Myers Squibb obtained Fast Track designation from the U.S. FDA for BMS-986446 (PRX005), an anti-MTBR-tau-targeting antibody, for the treatment of Alzheimer’s disease Prothena will convene an Extraordinary General Meeting on November 19, 2025 to obtain shareholder approval on a proposal reducing share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
SES Delivers Solid 9 Months and Q3 2025 Results November 6, 2025 SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the nine months and three months ended 30 September 2025 with solid operational and financial performance. Solid 9 months 2025 financial performance on a reported basis (Intelsat fully consolidated from 17 July 2025) Revenue of €1,747 million (+19.8% yoy(1)) and Adjusted [...]